The efficacy of oral piroxicam fast-dissolving tablets versus sublingual fentanyl in incident breakthrough pain due to bone metastases: a double-blinded randomized study
- 88 Downloads
Breakthrough pain (BTP) is a transient exacerbation of pain occurring in a patient with chronic, persistent pain. The most common type is incident pain that is mostly related to bone metastases. The oral mucosa is an attractive route for drug delivery. Sublingual fentanyl preparations are a very attractive agent in controlling attacks of BTP due to its rapid absorption through the oral mucosa. Non-steroidal anti-inflammatory drugs (NSAIDs) play a key role as a first step in treatment of cancer pain; piroxicam sublingual formulations could be a useful alternative in controlling incident pain. Our study hypothesis is to evaluate the efficacy of sublingual fentanyl versus oral piroxicam fast-dissolving tablets in patients with incident pain and its impact on functional status.
Patients and methods
A cohort of 100 adults of both genders suffering from bone metastases. Patients were assigned to receive either sublingual fentanyl tablet (group 1) or oral piroxicam fast-dissolving tablets (group 2). The pain intensity reduction on a 0–10 visual analog scale (VAS), frequency of BTP attacks, and onset of pain relief. Secondary end points included the functional interference items of the Brief Pain Inventory (BPI).
There is no significant difference between the two groups regarding the patients’ demographics. Significant decline of the VAS in each group in comparison to the pretreatment values (p = 0.001). Non-significant changes of the VAS, duration of pain attacks, and number of rescue doses in comparing both groups were measured. There was significant reduction in group 2 BPI regarding the relation with others, sleep pattern and enjoyment of life parameters at 2 and 4 weeks (p = 0.001).
Our study demonstrated that oral piroxicam fast-dissolving tablet is an analgesic alternative to sublingual fentanyl in patients with bone metastasis to control incidental BTP attacks with more favorable cost-benefit values.
KeywordsOral piroxicam tablets Sublingual fentanyl Incident BTP Bone metastases
The authors would like to thank the hospital pharmacist and the nursing staff of the pain clinic who participated in the study; in addition, we thank Prof Ibrahem Al-kabbash, our study statistician.
Compliance with ethical standards
The study was approved by an Investigational Review Board of the Faculty of Medicine, Tanta University; an informed written consent was obtained from all patients participating in the study. This study was registered in the clinical trials registry (clinicaltrials.gov) with a unique identification number NCT02382653.
Conflict of interest
The authors declare that they have no conflict of interest.
- 5.Omoti AE, Omoti CE (2007) Pharmacological strategies for the management of cancer pain in developing countries. Pharm Pract 5(3):99–104Google Scholar
- 15.Janecki M, Janecka J (2011) Breakthrough pain in patients with chronic cancer pain followed by palliative care and pain clinic physicians — an observational study. Palliat Med 10(1):29–34Google Scholar
- 21.Jandhyala R, Fullarton JR, Bennett MI (2013) Efficacy of rapid-onset oral fentanyl formulations vs. oral morphine for cancer-related breakthrough pain: a meta-analysis of comparative trials. J Pain Symptom Manag 12:1–8Google Scholar
- 22.Shimoyama N, Gomyo I, Teramoto O, Kojima K, Higuchi H, Yukitoshi N, Ohta E, Shimoyama M (2015) Efficacy and safety of sublingual fentanyl orally disintegrating tablet at doses determined from oral morphine rescue doses in the treatment of breakthrough cancer pain. Jpn J Clin Oncol 45(2):189–196CrossRefPubMedGoogle Scholar